Kazia Therapeutics (KZIA) Receivables - Net (2009 - 2025)

Kazia Therapeutics has reported Receivables - Net for 15 years, with the latest figure at $207175.2 in Q4 2025.

• For the quarter ending Q4 2025, Receivables - Net rose 229.55% year-over-year to $207175.2; the trailing twelve-month figure through Dec 2025 stood at $207175.2 (up 229.55% YoY), and the FY2025 full-year result was $62705.5, down 97.56% from the prior year.
• Receivables - Net for Q4 2025 stood at $207175.2, up from $62705.5 in the prior quarter.
• The five-year high for Receivables - Net was $2.6 million in Q2 2023, with the low at $55154.8 in Q4 2021.
• Historically, Receivables - Net has averaged $1.1 million across 5 years, with a median of $136177.8 in 2025.
• Annual changes were most pronounced in 2022 — Receivables - Net soared 4325.72% — and 2025, when it plunged 97.56%.
• Kazia Therapeutics' Receivables - Net stood at $55154.8 in 2021, then surged by 4325.72% to $2.4 million in 2022, then declined by 0.19% to $2.4 million in 2023, then slumped by 97.42% to $62866.2 in 2024, then jumped by 229.55% to $207175.2 in 2025.
• The last three Receivables - Net figures came in at $207175.2 (Q4 2025), $62705.5 (Q2 2025), and $62866.2 (Q4 2024), per Business Quant data.